GSBR-1290 is under clinical development by Structure Therapeutics and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GSBR-1290’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GSBR-1290 overview

GSBR-1290 is under development for the treatment of type 2 diabetes and obesity. It is administered through oral route. The therapeutic candidate acts as glucagon-like peptide-1 (GLP1) receptor agonist.

Structure Therapeutics overview

Structure Therapeutics is a health tech company that provides life-changing medicines for patients using advanced computational and structure-based technology. Structure Therapeutics is headquartered in South San Francisco, California, the US.

For a complete picture of GSBR-1290’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.